Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
Respiratory Research
Published in: Respiratory Research 1/2016

Open Access 01-12-2016 | Letter to the Editor

Effects of inhaled high-molecular weight hyaluronan in inflammatory airway disease

Authors: Adelaida Lamas, Jamie Marshburn, Vandy P. Stober, Scott H. Donaldson, Stavros Garantziotis

Published in: Respiratory Research | Issue 1/2016

Login to get access

Abstract

Cystic fibrosis (CF) is a chronic inflammatory disease that is affecting thousands of patients worldwide. Adjuvant anti-inflammatory treatment is an important component of cystic fibrosis treatment, and has shown promise in preserving lung function and prolonging life expectancy. Inhaled high molecular weight hyaluronan (HMW-HA) is reported to improve tolerability of hypertonic saline and thus increase compliance, and has been approved in some European countries for use as an adjunct to hypertonic saline treatment in cystic fibrosis. However, there are theoretical concerns that HMW-HA breakdown products may be pro-inflammatory. In this clinical pilot study we show that sputum cytokines in CF patients receiving HMW-HA are not increased, and therefore HMW-HA does not appear to adversely affect inflammatory status in CF airways.
Literature
1.
2.
Scuri M, Sabater JR, Abraham WM. Hyaluronan blocks porcine pancreatic elastase-induced mucociliary dysfunction in allergic sheep. J Appl Physiol (1985). 2007;102:2324–31.CrossRef
3.
Gavina M, Luciani A, Villella VR, Esposito S, Ferrari E, Bressani I, Casale A, Bruscia EM, Maiuri L, Raia V. Nebulized hyaluronan ameliorates lung inflammation in cystic fibrosis mice. Pediatr Pulmonol. 2013;48:761–71.CrossRefPubMed
4.
Ros M, Casciaro R, Lucca F, Troiani P, Salonini E, Favilli F, Quattrucci S, Sher D, Assael BM. Hyaluronic acid improves the tolerability of hypertonic saline in the chronic treatment of cystic fibrosis patients: a multicenter, randomized, controlled clinical trial. J Aerosol Med Pulm Drug Deliv. 2014;27:133–7.CrossRefPubMed
5.
Furnari ML, Termini L, Traverso G, Barrale S, Bonaccorso MR, Damiani G, Lo Piparo C, Collura M. Nebulized hypertonic saline containing hyaluronic acid improves tolerability in patients with cystic fibrosis and lung disease compared with nebulized hypertonic saline alone: a prospective, randomized, double-blind, controlled study. Ther Adv Respir Dis. 2012;6:315–22.CrossRefPubMed
6.
Cantor JO. Potential therapeutic applications of hyaluronan in the lung. Int J Chron Obstruct Pulmon Dis. 2007;2:283–8.PubMedPubMedCentral
7.
Cantor JO, Cerreta JM, Ochoa M, Ma S, Chow T, Grunig G, Turino GM. Aerosolized hyaluronan limits airspace enlargement in a mouse model of cigarette smoke-induced pulmonary emphysema. Exp Lung Res. 2005;31:417–30.CrossRefPubMed
8.
Garantziotis S, Li Z, Potts EN, Kimata K, Zhuo L, Morgan DL, Savani RC, Noble PW, Foster WM, Schwartz DA, Hollingsworth JW. Hyaluronan mediates ozone-induced airway hyperresponsiveness in mice. J Biol Chem. 2009;284:11309–17.CrossRefPubMedPubMedCentral
9.
Buonpensiero P, De Gregorio F, Sepe A, Di Pasqua A, Ferri P, Siano M, Terlizzi V, Raia V. Hyaluronic acid improves “pleasantness” and tolerability of nebulized hypertonic saline in a cohort of patients with cystic fibrosis. Adv Ther. 2010;27:870–8.CrossRefPubMed
10.
Allegra L, Abraham WM, Fasano V, Petrigni G. Methacholine challenge in asthmatics is protected by aerosolised hyaluronan at high (1,000 kDa) but not low (300 kDa) molecular weight. G Ital Mal Torace. 2008;62:297–301.
11.
Allegra L, Della Patrona S, Petrigni G. Hyaluronic acid: perspectives in lung diseases. Handb Exp Pharmacol. 2012;(207):385–401.
12.
Petrigni G, Allegra L. Aerosolised hyaluronic acid prevents exercise-induced bronchoconstriction, suggesting novel hypotheses on the correction of matrix defects in asthma. Pulm Pharmacol Ther. 2006;19:166–71.CrossRefPubMed
13.
Cantor JO, Cerreta JM, Ochoa M, Ma S, Liu M, Turino GM. Therapeutic effects of hyaluronan on smoke-induced elastic fiber injury: does delayed treatment affect efficacy? Lung. 2011;189:51–6.CrossRefPubMed
14.
Cantor JO, Shteyngart B, Cerreta JM, Liu M, Armand G, Turino GM. The effect of hyaluronan on elastic fiber injury in vitro and elastase-induced airspace enlargement in vivo. Proc Soc Exp Biol Med. 2000;225:65–71.CrossRefPubMed
15.
Cantor JO, Turino GM. Can exogenously administered hyaluronan improve respiratory function in patients with pulmonary emphysema? Chest. 2004;125:288–92.CrossRefPubMed
16.
Lazrak A, Jurkuvenaite A, Ness EC, Zhang S, Woodworth BA, Muhlebach MS, Stober VP, Lim YP, Garantziotis S, Matalon S. Inter-alpha-inhibitor blocks epithelial sodium channel activation and decreases nasal potential differences in DeltaF508 mice. Am J Respir Cell Mol Biol. 2014;50:953–62.CrossRefPubMedPubMedCentral
17.
Liang J, Jiang D, Jung Y, Xie T, Ingram J, Church T, Degan S, Leonard M, Kraft M, Noble PW. Role of hyaluronan and hyaluronan-binding proteins in human asthma. J Allergy Clin Immunol. 2011;128:403–11. e403.CrossRefPubMedPubMedCentral
18.
Broughton-Head VJ, Shur J, Carroll MP, Smith JR, Shute JK. Unfractionated heparin reduces the elasticity of sputum from patients with cystic fibrosis. Am J Physiol Lung Cell Mol Physiol. 2007;293:L1240–9.CrossRefPubMed
19.
Serisier DJ, Shute JK, Hockey PM, Higgins B, Conway J, Carroll MP. Inhaled heparin in cystic fibrosis. Eur Respir J. 2006;27:354–8.CrossRefPubMed
20.
Cantor JO, Cerreta JM, Armand G, Turino GM. Aerosolized hyaluronic acid decreases alveolar injury induced by human neutrophil elastase. Proc Soc Exp Biol Med. 1998;217:471–5.CrossRefPubMed
Metadata
Title
Effects of inhaled high-molecular weight hyaluronan in inflammatory airway disease
Authors
Adelaida Lamas
Jamie Marshburn
Vandy P. Stober
Scott H. Donaldson
Stavros Garantziotis
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Respiratory Research / Issue 1/2016
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/s12931-016-0442-4

Other articles of this Issue 1/2016

Respiratory Research 1/2016 Go to the issue

Erratum

Erratum to: Glycyrrhizin, inhibitor of high mobility group box-1, attenuates monocrotaline-induced pulmonary hypertension and vascular remodeling in rats

Research

Evidence for harm reduction in COPD smokers who switch to electronic cigarettes

Research

Possible role of Krüppel-like factor 5 in the remodeling of small airways and pulmonary vessels in chronic obstructive pulmonary disease

Editorial

Endothelial to mesenchymal transition (EndMT): an active process in Chronic Obstructive Pulmonary Disease (COPD)?

Research

Screening and managing obstructive sleep apnoea in nocturnal heart block patients: an observational study

Research

Extracellular ATP is involved in dsRNA-induced MUC5AC production via P2Y2R in human airway epithelium

ACC 2024 Congress Coverage

Cardiology Video

Highlights from the ACC 2024 Congress

Watch now

Watch official videos from the ACC congress summarizing key highlights from the last year in heart failure, cardiomyopathies, valvular disease, pulmonary vascular disease, and pediatric cardiology.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits